According
to the study, the global oligonucleotide
synthesis market is likely to grow
from $1.3 billion in 2016 to $2.7 billion by 2023. Recent technological and other advances, leading to
cost effective and rapid synthesis of oligomers, increased government funding
and other initiatives, have been driving the global oligonucleotide
synthesis market. The market is further expected to gain revenue from increased
focus on personalized medicine, offering tailored medical treatment to
individual characteristics, needs and preferences of patients and rising
compliance for oligonucleotide synthesis in the emerging economies.
Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/oligonucleotide-synthesis-market
Insights
on market segments
As
per the findings of research, globally synthesized oligonucleotide is the largest
product of oligonucleotide synthesis market, followed by reagents and
equipment. Based on application, synthesized oligonucleotide finds largest
application in research, followed by diagnostic and therapeutic.
North America stands as
the largest oligonucleotide synthesis market
Geographically,
North America has been the largest market for oligonucleotide synthesis market,
with the U.S. being the largest contributor to the regional market. In Europe,
the U.K. has been the largest region contributing to oligonucleotide synthesis
market, followed by Germany and France.
Key players in the oligonucleotide
synthesis market actively seeking acquisitions
The
oligonucleotide synthesis market has witnessed number of mergers and
acquisitions and strategic alliances recently. The companies are actively
seeking acquisitions to broaden their portfolio of life sciences
products. In 2015, Merck completed the acquisition of Sigma-Aldrich Co. LLC
that manufactures biochemical, organic chemical products, kits and services. In December 2016, Ajinomoto Co. Inc. announced the acquisition of
GeneDesign, Inc. to tap the growing demand of CDMOs for nucleic acid drugs in
the Japanese market. In December 2015, Integrated DNA Technologies Inc. announced
acquisition of the oligonucleotide synthesis business of AITbiotech Pte. Ltd.,
based in Singapore. The company aims to widen its customer base in the
Southeast Asian market through this acquisition.
The
major players including GE healthcare, Thermo Fisher Scientific Inc.,
Integrated DNA Technologies, Inc., Trilink Biotechnologies LLC, Eurogentec S.A.,
and Merck KGaA offer products across all the segments of the market. Some of the other key
players in the market include LGC Biosearch Technologies,
Inc., Bioautomation Corporation, Integrated DNA Technologies, Inc., GeneDesign,
Inc., Trilink Biotechnologies LLC, Merck KGaA, Eurofins Scientific SE, Thermo
Fisher Scientific Inc., General Electric Company and Eurogentec S.A.
No comments:
Post a Comment